



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

U.S. offers patients faster, greater access to cancer drugs than Europe

Whether better access leads to better health outcomes is still not determined

- Between 2000 and 2011, new oncology drug approvals in the U.S. outpaced European approvals by 33%.
- Regulatory approval in Europe does not imply reimbursement, as the evidence threshold for reimbursement is higher than in the U.S.
- Patient cost sharing is significantly lower in Europe than in the U.S.
- Oncology drug prices in Europe, on average, are 9% lower than in the U.S.
- Multiple systems of evaluation within Europe lead to widely varying periods of time required by reimbursement authorities to make reimbursement decisions.